Guardian Capital Group Limited (TSX: GCG; GCG.A) Announces

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
38
Guardian Capital Group Limited (TSX: GCG; GCG.A) Announces 2017 Second Quarter Operating Results

TORONTO, Aug. 10, 2017 (GLOBE NEWSWIRE) --

All per share figures disclosed below are stated on a diluted basis.

For the periods ended June 30Three monthsSix months
($ in thousands, except per share amounts) 2017 2016 2017 2016
     
Net revenue$37,208 $34,191$75,826 $69,261
Operating earnings 12,160 10,300 24,618 21,650
Net gains 10,783 1,028 28,372 17,806
Net earnings available to shareholders 19,387 8,887 44,390 32,705
     
     
EBITDA(1)$13,470 $11,607$26,776 $24,085
Adjusted cash flow(1) 10,859 9,435 15,276 19,018
     
     
Per share:    
Net earnings available to shareholders$0.67 $0.30$1.52 $1.09
EBITDA(1) 0.46 0.39 0.92 0.80
Adjusted cash flow(1) 0.37 0.32 0.53 0.64
     
     
As at  2017 2016
($ in millions, except per share amounts) June 30December 31June 30
     
Assets under management $26,379 $27,280$25,654
Assets under administration  17,073 16,489 15,425
Shareholders' equity  603 580 514
Securities  627 620 540
     
     
Per share:    
Shareholders' equity(1) $20.54 $19.62$17.10
Securities(1)  21.35 20.97 17.96
     

The Company’s operating earnings for the quarter ended June 30, 2017 were $12.2 million, an 18% increase, compared to $10.3 million in the same period a year earlier.  All segments of the Company contributed positively to the growth.  This increase was achieved while continuing to invest in developing operations in the UK and the US.  The operating losses related to these two initiatives in the current quarter were $1.5 million, $0.6 million higher than the losses incurred in the same quarter in the prior year.  These investments will continue to have a dampening effect on earnings in the short term, but are expected, over the long term, to improve future operating earnings.

Net gains in the current quarter were $10.8 million, compared to $1.0 million in the prior period, largely as a result of net gains realized within the investment funds consolidated by the Company.

Net earnings available to shareholders for the current quarter increased to $19.4 million, or $0.67 per share, compared to $8.9 million, or $0.30 per share a year earlier, resulting from the increased operating earnings and net gains, as described above.

The Company’s assets under management as at June 30, 2017 were $26.4 billion, an increase of 3% from $25.7 billion at June 30, 2016 but a decrease of 3% from $27.3 billion at the end of 2016.  Assets under administration at the end of the current quarter were $17.1 billion, an 11% increase from $15.4 billion at June 30, 2016, and up 4% from $16.5 billion at the end of 2016.

EBITDA for the current quarter was $13.5 million, or $0.46 per share, compared to $11.6 million, or $0.39 per share in 2016. Adjusted cash flow from operations for the current quarter was $10.9 million, or $0.37 per share, compared to $9.4 million, or $0.32 per share in 2016.

The Company’s shareholders’ equity as at June 30, 2017 was $603 million, or $20.54 per share, compared to $580 million, or $19.62 per share as at December 31, 2016 and $514 million, or $17.10 per share as at June 30, 2016. The Company’s securities as at June 30, 2017 were valued at $627 million, or $21.35 per share, compared to $620 million, or $20.97 per share, as at December 31, 2016 and $540 million, or $17.96 per share, as at June 30, 2016.

The Board of Directors has declared a quarterly eligible dividend of $0.10 per share, payable on October 18, 2017, to shareholders of record on October 11, 2017. 

The following table summarizes the Company's financial results for the past eight quarters.

         
Three months endedJune 30, 2017March 31, 2017December 31, 2016September 30, 2016June 30, 2016March 31, 2016December 31, 2015September 30, 2015
($ in thousand, except per share amounts)
         
Net revenue$37,208 $38,618$38,240$35,185$34,191$35,070$34,353$33,188 
Operating earnings 12,160 12,458 12,371 10,646 10,300 11,350 10,256 10,876 
Net gains (losses) 10,783 17,589 10,754 10,057 1,028 16,778 9,658 (2,407)
Net earnings 19,638 25,518 19,859 17,475 9,169 24,072 17,362 6,278 
Net earnings available to shareholders 19,387 25,003 19,417 17,353 8,887 23,818 17,138 6,053 
Shareholders' equity 603,428 605,039 580,177 545,339 513,939 497,656 504,255 470,533 
         
         
Net earnings available to shareholders      
per Class A and Common share      
Basic$0.70 $0.91$0.69$0.61$0.31$0.83$0.59$0.21 
Diluted 0.67 0.86 0.65 0.58 0.30 0.79 0.56 0.20 
         
Shareholders' equity per Class A and      
Common share (1)       
Basic$21.75 $21.81$20.75$19.11$18.08$17.51$17.37$15.96 
Diluted 20.54 20.58 19.62 18.07 17.10 16.63 16.55 15.23 
         
Dividends paid$0.100$0.085$0.085$0.085$0.085$0.075$0.075$0.075 
         

Guardian Capital Group Limited is a diversified financial services company founded in 1962.  The Company provides institutional and high net worth investment management services to clients; financial services to international investors; and services to financial advisors in its national mutual fund dealer, securities dealer, and insurance distribution network.  Its Common and Class A shares are listed on The Toronto Stock Exchange.

(1) The Company's management uses EBITDA, EBITDA per share, Adjusted cash flow from operations, Adjusted cash flow from operations per share, Shareholders' equity per share and Securities per share to evaluate and assess the performance of its business.  These measures do not have standardized measures under International Financial Reporting Standards ("IFRS"), and are therefore unlikely to be comparable to similar measures presented by other companies.  However, management believes that most shareholders, creditors, other stakeholders and investment analysts prefer to include the use of these measures in analyzing the Company's results.  The Company defines EBITDA as net earnings before interest, income taxes, amortization, stock-based compensation, net gains or losses, less amounts attributable to non-controlling interests.  The Company defines Adjusted cash flow from operations as net cash from operating activities, net of changes in non-cash working capital items and non-controlling interests.  The most comparable IFRS measures are Net earnings, which were $19,638 for the three months ended June 30, 2017 (2016 - $9,169), and Net cash from operating activities, which was $14,541 for the three months ended June 30, 2017 (2016 - $13,294).  The per share amounts for EBITDA, Adjusted cash flow from operations, Shareholders' equity and Securities are calculated by dividing the amounts by diluted shares, which Is calculated in a similar manner as net earnings available to shareholders per share.  More detailed descriptions of these non-IFRS measures are provided in the Company's quarterly Management's Discussions and Analysis, including a reconciliation of these measures to their most comparable IFRS measures. 

For further information, contact: Donald Yi  Chief Financial Officer (416) 350-3136 George Mavroudis President and Chief Executive Officer (416) 364-8341

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fosun Pharma Hits the Buyback Button: What's Next?

Updated Category News Views 0

Fosun Pharma's Bold Move Well, if this isn't Fosun Pharma making some noise! Announcing an H-share repurchase plan worth up to HK$1 billion is like setting off fireworks amidst any investor's evening. They're hollering to the market, 'We see value, and we're doubling down on it.' Crunching the Numbers In the first half of 2026, Fosun Pharma's numbers weren't just a flash...

Continue Reading
Harbour BioMed Joins Stock Connect, Boosts Investor Access

Updated Category News Views 1

The Big Leap: Harbour BioMed Joins Stock Connect Well, if this ain't something to get excited about—Harbour BioMed just snagged a spot on the Stock Connect roster. This step isn't just ceremonial. We're talking about real access for mainland Chinese investors to dive directly into the shares of Harbour BioMed (HKEX: 02142.HK) through the Shanghai-Hong Kong and...

Continue Reading
Bad Bunny Super Bowl Halftime Show Sweeps 7 Emmy Wins

Updated Category News Views 3

An Unprecedented Performance: A Halftime Show for the Ages Hold onto your hats, folks—Bad Bunny and his Super Bowl LX Halftime Show have taken home a jaw-dropping seven Emmys at the 78th Emmy Awards. This is uncharted territory for any Super Bowl Halftime Show. Never before has a halftime spectacle swept the Emmys like this. We’re talking about categories such as...

Continue Reading
Asia-Pacific Media Forum Eyes Future Growth Strategies

Updated Category News Views 2

Media Heavyweights Converge in Shenzhen Picture this: Over 400 media moguls from the Asia-Pacific region, huddled together in Shenzhen under that blazing September sun. What for? They're on a mission, inspecting China's shifting landscape, hunting down fresh growth avenues in the Guangdong-Hong Kong-Macao Greater Bay Area. It kicks off within the walls of the Asia-Pacific...

Continue Reading
Aroa Biosurgery Reports Low Infection Rates: A Milestone

Updated Category News Views 1

Peer-Reviewed Study: Aroa's Myriad Shows Low Infection Rates Seems like the folks at Aroa Biosurgery have got something solid to brag about in the world of complex soft tissue reconstruction. The company just released interim results from their massive MASTRR Registry study, and the numbers are looking pretty darn promising. We're talking about a 411-patient analysis...

Continue Reading
EyePoint Stumbles: Legal Eagles Circle Post-Trial Flop

Updated Category News Views 2

EyePoint Slips on Clinical Banana Peel Well, if EyePoint was aiming for a splash, they sure got it—just not the kind they were hoping for. News dropped like a lead balloon when EyePoint announced their Phase 3 DURAVYU trial results for wet age-related macular degeneration, revealing they missed their primary endpoint. And what did that mean for their stock? A death...

Continue Reading
Mermaid Folklore Meets Revolution in New Short Film

Updated Category News Views 2

A Sea Haunting Like No Other Ever feel like history's forgotten tales deserve a fresh spin? Well, this one's shaking it up! Hoyt Dwyer, an Atlanta filmmaker, flips the script on a lesser-known bit from the American Revolution. Yeah, we're talking about Hessian soldiers and sirens here. Just hang on to your hats because this ain't your typical historical retelling. A...

Continue Reading
Creality Rolls Out K3, SPARKX i8 at IFA 2026

Updated Category News Views 12

Creality Struts Its Stuff at IFA 2026 You wouldn't guess 3D printing had anything left to dazzle us with, but Creality has sure put those notions to rest at the IFA 2026 in Berlin. They're rolling out the big guns with fresh tech that pushes both efficiency and sustainability—two big buzzwords these days—and ties a neat little bow on their innovative streak....

Continue Reading
Ice-Rock Avalanches: Future Risks and Urgent Lessons

Updated Category News Views 1

Mounting Threats in Mountain Chains That nightmare on August 26 at Mount Langtang Lirung in Nepal—where an ice-rock avalanche triggered a catastrophic mudslide—brought a harsh reminder that these mountains are cracking wide open. With 31 dead and over 500 souls still unaccounted for, it's a chilling warning about how vulnerable high-altitude regions have become. A...

Continue Reading

Top 5 Most Recently Viewed Articles

Aterian Prepares for Upcoming Earnings Call This Quarter

Updated Category News Views 99

Aterian's Upcoming Financial Results Announcement Aterian, Inc. (Nasdaq: ATER), a prominent player in the consumer products sector, is gearing up to reveal its financial performance for the second quarter. Scheduled for Wednesday in the coming week, this announcement will take place after market closure, providing investors with valuable insights into the company’s...

Continue Reading
Analyzing RTX: Trends in Short Interest and Market Sentiment

Updated Category News Views 176

Understanding RTX's Recent Market Movements RTX Corp has seen a notable shift in its market dynamics recently. The company's short interest, defined as the number of shares sold short but not yet covered, has decreased by 7.63% since the last reporting period. Currently, there are approximately 16.18 million shares sold short, equating to 1.21% of all shares available for...

Continue Reading
Celebrate Christmas Spirit with Personalized PrayerSongs

Updated Category News Views 156

Celebrate the Joy of Christmas with PrayerSong Bring Love Into Your Home with a PrayerSong for Your Family and Friends When the holiday season arrives, the focus shifts beyond material gifts. Instead, it’s about nurturing connections filled with love, faith, and meaningful moments. This Christmas, PrayerSong provides families with a unique opportunity to honor loved...

Continue Reading
Understanding the Short Selling Landscape of Analog Devices

Updated Category News Views 153

Analyzing Short Interest for Analog Devices As investors navigate the ever-changing stock market, understanding short interest can provide valuable insights into market sentiment regarding Analog Devices (NYSE: ADI). Recently, it was reported that Analog Devices has seen a notable increase of 4.11% in its short percent of float. Currently, there are approximately 7.52...

Continue Reading
Future of Clinical Trials: Exploring Market Growth to USD 85.37 Billion

Updated Category News Views 71

Understanding Clinical Trials and Their Importance Clinical trials serve as a fundamental pillar in advancing medical knowledge and enhancing patient care. These trials encompass a detailed and thorough process involving participant recruitment, intervention administration, data collection, and result analysis. The outcomes produced from clinical trials play a crucial...

Continue Reading